Chemistry, mode of action and clinical efficacy of the anticancer diterpenoid tigilanol tigliate (EBC-46)

Planta Med 2019; 85(18): 1404-1405
DOI: 10.1055/s-0039-3399676

Abstracts of Plenary Lectures

G Appendino

¹Dipartimento di Scienze del Farmaco, Largo Donegani, 28100 Novara, Italy

,

A Pagani

¹Dipartimento di Scienze del Farmaco, Largo Donegani, 28100 Novara, Italy

,

C Williams

²School of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, Australia

,

J Cullen

³Drug Discovery Group, QIMR Berghofer Medical Research Institute, Brisbane, Australia

,

G Boyle

³Drug Discovery Group, QIMR Berghofer Medical Research Institute, Brisbane, Australia

,

P Parsons

³Drug Discovery Group, QIMR Berghofer Medical Research Institute, Brisbane, Australia

,

J Campbell

⁴QBiotics Group Ltd, Yungaburra, Queensland, Australia

,

V Gordon

⁴QBiotics Group Ltd, Yungaburra, Queensland, Australia

,

P Schmidt

⁴QBiotics Group Ltd, Yungaburra, Queensland, Australia

,

P Reddell

⁴QBiotics Group Ltd, Yungaburra, Queensland, Australia

References
1 Barnett CME, Broit N, Ya PY, Cullen JK, Parsons PG, Panizza BJ. et al. Optimising intratumoral treatment of head and neck squamous cell carcinoma models with the diterpene ester Tigilanol tiglate. Invest New Drugs 2019; 37: 1-8.
2 Miller J, Campbell J, Blum A, Reddell P, Gordon V, Schmidt P. et al. Dose characterization of the investigational anticancer drug tigilanol tiglate (EBC-46) in the local treatment of canine mast cell tumors. Front Vet Sci 2019; 6: 106.